 | • レポートコード：QYR2104Z3999 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、筋緊張性ジストロフィー治療薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（ナトリウムチャネル遮断薬、三環系抗うつ薬、その他）、用途別市場規模（病院薬局、ドラッグストア、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・筋緊張性ジストロフィー治療薬の市場動向 ・企業の競争状況、市場シェア ・筋緊張性ジストロフィー治療薬の種類別市場規模（ナトリウムチャネル遮断薬、三環系抗うつ薬、その他） ・筋緊張性ジストロフィー治療薬の用途別市場規模（病院薬局、ドラッグストア、その他） ・筋緊張性ジストロフィー治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・筋緊張性ジストロフィー治療薬のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・筋緊張性ジストロフィー治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・筋緊張性ジストロフィー治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・筋緊張性ジストロフィー治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Lupin、Teva、ANI Pharmaceuticals、Mylan、Novartis、Sun Pharma、Mallinckrodt） ・結論 |
Myotonic dystrophy is a type of muscular dystrophy, a group of long-term genetic disorders that impair muscle function. Symptoms include gradually worsening muscle loss and weakness. Muscles often contract and are unable to relax. Other symptoms may include cataracts, intellectual disability and heart conduction problems. In men, there may be early balding and an inability to have children.
Market Analysis and Insights: Global Myotonic Dystrophy Medication Market
The global Myotonic Dystrophy Medication market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Myotonic Dystrophy Medication market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Myotonic Dystrophy Medication market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Myotonic Dystrophy Medication market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Myotonic Dystrophy Medication market.
Global Myotonic Dystrophy Medication Scope and Market Size
Myotonic Dystrophy Medication market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Myotonic Dystrophy Medication market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Sodium Channel Blocker
Tricyclic Antidepressant
Other
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Lupin
Teva
ANI Pharmaceuticals
Mylan
Novartis
Sun Pharma
Mallinckrodt
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Myotonic Dystrophy Medication Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Sodium Channel Blocker
1.2.3 Tricyclic Antidepressant
1.2.4 Other
1.3 Market by Application
1.3.1 Global Myotonic Dystrophy Medication Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Myotonic Dystrophy Medication Market Perspective (2016-2027)
2.2 Myotonic Dystrophy Medication Growth Trends by Regions
2.2.1 Myotonic Dystrophy Medication Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Myotonic Dystrophy Medication Historic Market Share by Regions (2016-2021)
2.2.3 Myotonic Dystrophy Medication Forecasted Market Size by Regions (2022-2027)
2.3 Myotonic Dystrophy Medication Industry Dynamic
2.3.1 Myotonic Dystrophy Medication Market Trends
2.3.2 Myotonic Dystrophy Medication Market Drivers
2.3.3 Myotonic Dystrophy Medication Market Challenges
2.3.4 Myotonic Dystrophy Medication Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Myotonic Dystrophy Medication Players by Revenue
3.1.1 Global Top Myotonic Dystrophy Medication Players by Revenue (2016-2021)
3.1.2 Global Myotonic Dystrophy Medication Revenue Market Share by Players (2016-2021)
3.2 Global Myotonic Dystrophy Medication Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Myotonic Dystrophy Medication Revenue
3.4 Global Myotonic Dystrophy Medication Market Concentration Ratio
3.4.1 Global Myotonic Dystrophy Medication Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Myotonic Dystrophy Medication Revenue in 2020
3.5 Myotonic Dystrophy Medication Key Players Head office and Area Served
3.6 Key Players Myotonic Dystrophy Medication Product Solution and Service
3.7 Date of Enter into Myotonic Dystrophy Medication Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Myotonic Dystrophy Medication Breakdown Data by Type
4.1 Global Myotonic Dystrophy Medication Historic Market Size by Type (2016-2021)
4.2 Global Myotonic Dystrophy Medication Forecasted Market Size by Type (2022-2027)
5 Myotonic Dystrophy Medication Breakdown Data by Application
5.1 Global Myotonic Dystrophy Medication Historic Market Size by Application (2016-2021)
5.2 Global Myotonic Dystrophy Medication Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Myotonic Dystrophy Medication Market Size (2016-2027)
6.2 North America Myotonic Dystrophy Medication Market Size by Type
6.2.1 North America Myotonic Dystrophy Medication Market Size by Type (2016-2021)
6.2.2 North America Myotonic Dystrophy Medication Market Size by Type (2022-2027)
6.2.3 North America Myotonic Dystrophy Medication Market Size by Type (2016-2027)
6.3 North America Myotonic Dystrophy Medication Market Size by Application
6.3.1 North America Myotonic Dystrophy Medication Market Size by Application (2016-2021)
6.3.2 North America Myotonic Dystrophy Medication Market Size by Application (2022-2027)
6.3.3 North America Myotonic Dystrophy Medication Market Size by Application (2016-2027)
6.4 North America Myotonic Dystrophy Medication Market Size by Country
6.4.1 North America Myotonic Dystrophy Medication Market Size by Country (2016-2021)
6.4.2 North America Myotonic Dystrophy Medication Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Myotonic Dystrophy Medication Market Size (2016-2027)
7.2 Europe Myotonic Dystrophy Medication Market Size by Type
7.2.1 Europe Myotonic Dystrophy Medication Market Size by Type (2016-2021)
7.2.2 Europe Myotonic Dystrophy Medication Market Size by Type (2022-2027)
7.2.3 Europe Myotonic Dystrophy Medication Market Size by Type (2016-2027)
7.3 Europe Myotonic Dystrophy Medication Market Size by Application
7.3.1 Europe Myotonic Dystrophy Medication Market Size by Application (2016-2021)
7.3.2 Europe Myotonic Dystrophy Medication Market Size by Application (2022-2027)
7.3.3 Europe Myotonic Dystrophy Medication Market Size by Application (2016-2027)
7.4 Europe Myotonic Dystrophy Medication Market Size by Country
7.4.1 Europe Myotonic Dystrophy Medication Market Size by Country (2016-2021)
7.4.2 Europe Myotonic Dystrophy Medication Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Myotonic Dystrophy Medication Market Size (2016-2027)
8.2 Asia-Pacific Myotonic Dystrophy Medication Market Size by Type
8.2.1 Asia-Pacific Myotonic Dystrophy Medication Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Myotonic Dystrophy Medication Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Myotonic Dystrophy Medication Market Size by Type (2016-2027)
8.3 Asia-Pacific Myotonic Dystrophy Medication Market Size by Application
8.3.1 Asia-Pacific Myotonic Dystrophy Medication Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Myotonic Dystrophy Medication Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Myotonic Dystrophy Medication Market Size by Application (2016-2027)
8.4 Asia-Pacific Myotonic Dystrophy Medication Market Size by Region
8.4.1 Asia-Pacific Myotonic Dystrophy Medication Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Myotonic Dystrophy Medication Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Myotonic Dystrophy Medication Market Size (2016-2027)
9.2 Latin America Myotonic Dystrophy Medication Market Size by Type
9.2.1 Latin America Myotonic Dystrophy Medication Market Size by Type (2016-2021)
9.2.2 Latin America Myotonic Dystrophy Medication Market Size by Type (2022-2027)
9.2.3 Latin America Myotonic Dystrophy Medication Market Size by Type (2016-2027)
9.3 Latin America Myotonic Dystrophy Medication Market Size by Application
9.3.1 Latin America Myotonic Dystrophy Medication Market Size by Application (2016-2021)
9.3.2 Latin America Myotonic Dystrophy Medication Market Size by Application (2022-2027)
9.3.3 Latin America Myotonic Dystrophy Medication Market Size by Application (2016-2027)
9.4 Latin America Myotonic Dystrophy Medication Market Size by Country
9.4.1 Latin America Myotonic Dystrophy Medication Market Size by Country (2016-2021)
9.4.2 Latin America Myotonic Dystrophy Medication Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Myotonic Dystrophy Medication Market Size (2016-2027)
10.2 Middle East & Africa Myotonic Dystrophy Medication Market Size by Type
10.2.1 Middle East & Africa Myotonic Dystrophy Medication Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Myotonic Dystrophy Medication Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Myotonic Dystrophy Medication Market Size by Type (2016-2027)
10.3 Middle East & Africa Myotonic Dystrophy Medication Market Size by Application
10.3.1 Middle East & Africa Myotonic Dystrophy Medication Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Myotonic Dystrophy Medication Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Myotonic Dystrophy Medication Market Size by Application (2016-2027)
10.4 Middle East & Africa Myotonic Dystrophy Medication Market Size by Country
10.4.1 Middle East & Africa Myotonic Dystrophy Medication Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Myotonic Dystrophy Medication Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Lupin
11.1.1 Lupin Company Details
11.1.2 Lupin Business Overview
11.1.3 Lupin Myotonic Dystrophy Medication Introduction
11.1.4 Lupin Revenue in Myotonic Dystrophy Medication Business (2016-2021)
11.1.5 Lupin Recent Development
11.2 Teva
11.2.1 Teva Company Details
11.2.2 Teva Business Overview
11.2.3 Teva Myotonic Dystrophy Medication Introduction
11.2.4 Teva Revenue in Myotonic Dystrophy Medication Business (2016-2021)
11.2.5 Teva Recent Development
11.3 ANI Pharmaceuticals
11.3.1 ANI Pharmaceuticals Company Details
11.3.2 ANI Pharmaceuticals Business Overview
11.3.3 ANI Pharmaceuticals Myotonic Dystrophy Medication Introduction
11.3.4 ANI Pharmaceuticals Revenue in Myotonic Dystrophy Medication Business (2016-2021)
11.3.5 ANI Pharmaceuticals Recent Development
11.4 Mylan
11.4.1 Mylan Company Details
11.4.2 Mylan Business Overview
11.4.3 Mylan Myotonic Dystrophy Medication Introduction
11.4.4 Mylan Revenue in Myotonic Dystrophy Medication Business (2016-2021)
11.4.5 Mylan Recent Development
11.5 Novartis
11.5.1 Novartis Company Details
11.5.2 Novartis Business Overview
11.5.3 Novartis Myotonic Dystrophy Medication Introduction
11.5.4 Novartis Revenue in Myotonic Dystrophy Medication Business (2016-2021)
11.5.5 Novartis Recent Development
11.6 Sun Pharma
11.6.1 Sun Pharma Company Details
11.6.2 Sun Pharma Business Overview
11.6.3 Sun Pharma Myotonic Dystrophy Medication Introduction
11.6.4 Sun Pharma Revenue in Myotonic Dystrophy Medication Business (2016-2021)
11.6.5 Sun Pharma Recent Development
11.7 Mallinckrodt
11.7.1 Mallinckrodt Company Details
11.7.2 Mallinckrodt Business Overview
11.7.3 Mallinckrodt Myotonic Dystrophy Medication Introduction
11.7.4 Mallinckrodt Revenue in Myotonic Dystrophy Medication Business (2016-2021)
11.7.5 Mallinckrodt Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Myotonic Dystrophy Medication Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Sodium Channel Blocker
Table 3. Key Players of Tricyclic Antidepressant
Table 4. Key Players of Other
Table 5. Global Myotonic Dystrophy Medication Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Myotonic Dystrophy Medication Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Myotonic Dystrophy Medication Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Myotonic Dystrophy Medication Market Share by Regions (2016-2021)
Table 9. Global Myotonic Dystrophy Medication Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Myotonic Dystrophy Medication Market Share by Regions (2022-2027)
Table 11. Myotonic Dystrophy Medication Market Trends
Table 12. Myotonic Dystrophy Medication Market Drivers
Table 13. Myotonic Dystrophy Medication Market Challenges
Table 14. Myotonic Dystrophy Medication Market Restraints
Table 15. Global Myotonic Dystrophy Medication Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Myotonic Dystrophy Medication Market Share by Players (2016-2021)
Table 17. Global Top Myotonic Dystrophy Medication Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myotonic Dystrophy Medication as of 2020)
Table 18. Ranking of Global Top Myotonic Dystrophy Medication Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Myotonic Dystrophy Medication Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Myotonic Dystrophy Medication Product Solution and Service
Table 22. Date of Enter into Myotonic Dystrophy Medication Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Myotonic Dystrophy Medication Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Myotonic Dystrophy Medication Revenue Market Share by Type (2016-2021)
Table 26. Global Myotonic Dystrophy Medication Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Myotonic Dystrophy Medication Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Myotonic Dystrophy Medication Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Myotonic Dystrophy Medication Revenue Market Share by Application (2016-2021)
Table 30. Global Myotonic Dystrophy Medication Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Myotonic Dystrophy Medication Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Myotonic Dystrophy Medication Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Myotonic Dystrophy Medication Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Myotonic Dystrophy Medication Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Myotonic Dystrophy Medication Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Myotonic Dystrophy Medication Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Myotonic Dystrophy Medication Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Myotonic Dystrophy Medication Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Myotonic Dystrophy Medication Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Myotonic Dystrophy Medication Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Myotonic Dystrophy Medication Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Myotonic Dystrophy Medication Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Myotonic Dystrophy Medication Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Myotonic Dystrophy Medication Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Myotonic Dystrophy Medication Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Myotonic Dystrophy Medication Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Myotonic Dystrophy Medication Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Myotonic Dystrophy Medication Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Myotonic Dystrophy Medication Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Myotonic Dystrophy Medication Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Myotonic Dystrophy Medication Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Myotonic Dystrophy Medication Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Myotonic Dystrophy Medication Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Myotonic Dystrophy Medication Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Myotonic Dystrophy Medication Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Myotonic Dystrophy Medication Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Myotonic Dystrophy Medication Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Myotonic Dystrophy Medication Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Myotonic Dystrophy Medication Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Myotonic Dystrophy Medication Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Myotonic Dystrophy Medication Market Size by Country (2022-2027) & (US$ Million)
Table 62. Lupin Company Details
Table 63. Lupin Business Overview
Table 64. Lupin Myotonic Dystrophy Medication Product
Table 65. Lupin Revenue in Myotonic Dystrophy Medication Business (2016-2021) & (US$ Million)
Table 66. Lupin Recent Development
Table 67. Teva Company Details
Table 68. Teva Business Overview
Table 69. Teva Myotonic Dystrophy Medication Product
Table 70. Teva Revenue in Myotonic Dystrophy Medication Business (2016-2021) & (US$ Million)
Table 71. Teva Recent Development
Table 72. ANI Pharmaceuticals Company Details
Table 73. ANI Pharmaceuticals Business Overview
Table 74. ANI Pharmaceuticals Myotonic Dystrophy Medication Product
Table 75. ANI Pharmaceuticals Revenue in Myotonic Dystrophy Medication Business (2016-2021) & (US$ Million)
Table 76. ANI Pharmaceuticals Recent Development
Table 77. Mylan Company Details
Table 78. Mylan Business Overview
Table 79. Mylan Myotonic Dystrophy Medication Product
Table 80. Mylan Revenue in Myotonic Dystrophy Medication Business (2016-2021) & (US$ Million)
Table 81. Mylan Recent Development
Table 82. Novartis Company Details
Table 83. Novartis Business Overview
Table 84. Novartis Myotonic Dystrophy Medication Product
Table 85. Novartis Revenue in Myotonic Dystrophy Medication Business (2016-2021) & (US$ Million)
Table 86. Novartis Recent Development
Table 87. Sun Pharma Company Details
Table 88. Sun Pharma Business Overview
Table 89. Sun Pharma Myotonic Dystrophy Medication Product
Table 90. Sun Pharma Revenue in Myotonic Dystrophy Medication Business (2016-2021) & (US$ Million)
Table 91. Sun Pharma Recent Development
Table 92. Mallinckrodt Company Details
Table 93. Mallinckrodt Business Overview
Table 94. Mallinckrodt Myotonic Dystrophy Medication Product
Table 95. Mallinckrodt Revenue in Myotonic Dystrophy Medication Business (2016-2021) & (US$ Million)
Table 96. Mallinckrodt Recent Development
Table 97. Research Programs/Design for This Report
Table 98. Key Data Information from Secondary Sources
Table 99. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Myotonic Dystrophy Medication Market Share by Type: 2020 VS 2027
Figure 2. Sodium Channel Blocker Features
Figure 3. Tricyclic Antidepressant Features
Figure 4. Other Features
Figure 5. Global Myotonic Dystrophy Medication Market Share by Application: 2020 VS 2027
Figure 6. Hospital Pharmacy Case Studies
Figure 7. Retail Pharmacy Case Studies
Figure 8. Other Case Studies
Figure 9. Myotonic Dystrophy Medication Report Years Considered
Figure 10. Global Myotonic Dystrophy Medication Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Myotonic Dystrophy Medication Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Myotonic Dystrophy Medication Market Share by Regions: 2020 VS 2027
Figure 13. Global Myotonic Dystrophy Medication Market Share by Regions (2022-2027)
Figure 14. Global Myotonic Dystrophy Medication Market Share by Players in 2020
Figure 15. Global Top Myotonic Dystrophy Medication Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myotonic Dystrophy Medication as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Myotonic Dystrophy Medication Revenue in 2020
Figure 17. Global Myotonic Dystrophy Medication Revenue Market Share by Type (2016-2021)
Figure 18. Global Myotonic Dystrophy Medication Revenue Market Share by Type (2022-2027)
Figure 19. North America Myotonic Dystrophy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Myotonic Dystrophy Medication Market Share by Type (2016-2027)
Figure 21. North America Myotonic Dystrophy Medication Market Share by Application (2016-2027)
Figure 22. North America Myotonic Dystrophy Medication Market Share by Country (2016-2027)
Figure 23. United States Myotonic Dystrophy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Myotonic Dystrophy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Myotonic Dystrophy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Myotonic Dystrophy Medication Market Share by Type (2016-2027)
Figure 27. Europe Myotonic Dystrophy Medication Market Share by Application (2016-2027)
Figure 28. Europe Myotonic Dystrophy Medication Market Share by Country (2016-2027)
Figure 29. Germany Myotonic Dystrophy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Myotonic Dystrophy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Myotonic Dystrophy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Myotonic Dystrophy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Myotonic Dystrophy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Myotonic Dystrophy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Myotonic Dystrophy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Myotonic Dystrophy Medication Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Myotonic Dystrophy Medication Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Myotonic Dystrophy Medication Market Share by Region (2016-2027)
Figure 39. China Myotonic Dystrophy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Myotonic Dystrophy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Myotonic Dystrophy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Myotonic Dystrophy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Myotonic Dystrophy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Myotonic Dystrophy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Myotonic Dystrophy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Myotonic Dystrophy Medication Market Share by Type (2016-2027)
Figure 47. Latin America Myotonic Dystrophy Medication Market Share by Application (2016-2027)
Figure 48. Latin America Myotonic Dystrophy Medication Market Share by Country (2016-2027)
Figure 49. Mexico Myotonic Dystrophy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Myotonic Dystrophy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Myotonic Dystrophy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Myotonic Dystrophy Medication Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Myotonic Dystrophy Medication Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Myotonic Dystrophy Medication Market Share by Country (2016-2027)
Figure 55. Turkey Myotonic Dystrophy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Myotonic Dystrophy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Myotonic Dystrophy Medication Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Lupin Revenue Growth Rate in Myotonic Dystrophy Medication Business (2016-2021)
Figure 59. Teva Revenue Growth Rate in Myotonic Dystrophy Medication Business (2016-2021)
Figure 60. ANI Pharmaceuticals Revenue Growth Rate in Myotonic Dystrophy Medication Business (2016-2021)
Figure 61. Mylan Revenue Growth Rate in Myotonic Dystrophy Medication Business (2016-2021)
Figure 62. Novartis Revenue Growth Rate in Myotonic Dystrophy Medication Business (2016-2021)
Figure 63. Sun Pharma Revenue Growth Rate in Myotonic Dystrophy Medication Business (2016-2021)
Figure 64. Mallinckrodt Revenue Growth Rate in Myotonic Dystrophy Medication Business (2016-2021)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
世界のデュシェンヌ型筋ジストロフィー治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Duchenne Muscular Dystrophy Drugs Market The global Duchenne Muscular Dystrophy Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high da…- 世界のフレーバー動物用医薬品市場規模・現状・予測（2021年-2027年） Flavoring veterinary drugs are common veterinary drugs with flavor. Boehringer-ingelheim has more than 35% market share in the world, followed by Elanco Animal Health with 15% market share. Market Analysis and Insights: Global Flavored Veterinary Medication Market The global Flavored Veterinary Medi…
- 世界の非滅菌調剤医薬品市場規模・現状・予測（2021年-2027年） Nonsterile drug compounding is the practice of preparing specific medication doses for patients to drink, swallow, insert or apply to the skin. It is the most common kind of drug compounding done by pharmacists and pharmacy technicians in community and hospital pharmacies. And despite its "nonsteril…
- 世界の調剤自動化システム市場規模・現状・予測（2021年-2027年） Pharmacy Automation is the mechanization or automation of tasks and processes performed in pharmacy or other health care settings. It includes process like medication dispensing, packaging, labeling, storage and retrieval systems and table top counters. The pharmacy automation not only streamline ph…
- 世界の市販鎮痛薬市場規模・現状・予測（2021年-2027年） Over-the-counter pain medication are very helpful for the person suffering from minor and major pain. As the over-the-counter are easily available without proper prescriptions and very effective to control the pain. Over-the-counter pain medication are approved product from the regulatory authority,…